Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Stimulation par Courant Alternatif de Haute Intensité comme Thérapie de Neuromodulation pour le Trouble de l'Usage de l'Alcool : Une Étude Pilote (HITACS-AUD)

12 octobre 2026 mis à jour par: Shanghai Mental Health Center

Stimulation par courant alternatif de haute intensité en tant que thérapie de neuromodulation pour le trouble de l'usage d'alcool : une étude pilote

This one-arm pilot study aims to evaluate the preliminary clinical, behavioral, and neurophysiological effects of high-intensity transcranial alternating current stimulation (HI-tACS) in individuals with alcohol use disorder (AUD). Participants will receive HI-tACS and undergo clinical and neurophysiological assessments before and after the intervention.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

Alcohol use disorder (AUD) has become a major social and public health problem. Persistent alcohol craving, impaired self-control, and abnormalities in decision-making and inhibitory control are important clinical and cognitive features of AUD. High-intensity transcranial alternating current stimulation (HI-tACS) is a non-invasive neuromodulation approach that may have potential therapeutic effects in individuals with AUD. However, its clinical and neurobiological effects in AUD remain unclear. The investigators hypothesize that HI-tACS may reduce alcohol craving and improve self-regulation and cognitive-control functions in individuals with AUD. This one-arm pilot study aims to evaluate the preliminary effects and tolerability of a 2-week course of HI-tACS, using clinical assessments together with electroencephalographic, and magnetic resonance imaging measures to explore potential changes in craving, self-control, risky decision-making, inhibitory control, and related neural activity. This study may provide preliminary clinical and mechanistic evidence for the further development of HI-tACS as a potential intervention for AUD.

Type d'étude

Interventionnel

Inscription (Estimé)

18

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Jiang Du, MD, PhD.
  • Numéro de téléphone: +8602164906315
  • E-mail: dujiangdou@163.com

Lieux d'étude

      • Shanghai, Chine
        • Recrutement
        • Shanghai Mental Health Center
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Education level of junior high school or above, capable of completing questionnaires and behavioral tests;
  • Aged 18-60 years;
  • Meet DSM-5 diagnostic criteria for Alcohol Use Disorder;
  • No abnormal findings on physical examination;
  • Agree to participate in follow-up assessments;
  • No contraindications for MRI scanning.

Exclusion criteria:

  • Have impaired intelligence (Intelligence Quotient<70);
  • Prior tDCS or TMS treatment within the past 3 months;
  • Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy);
  • Severe somatic diseases or major organ dysfunction;
  • Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
  • Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
  • Diagnosis of other substance-related and addictive disorders or behavioral addictions.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: HI-tACS

A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD.

A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The change of alcohol craving
Délai: Baseline, immediately after completion of the 2-week intervention

Alcohol craving will be measured by the alcohol craving Visual Analog Scale (VAS). The total score of VAS ranged from 0 to 10, in which higher scores mean a higher level of alcohol craving.

Baseline, immediately after completion of the 2-week intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The change of drinking urge
Délai: Baseline, immediately after completion of the 2-week intervention

Alcohol urge will be assessed using the Alcohol Urge Questionnaire (AUQ). The total score of AUQ ranges from 8 to 56, with higher scores indicating stronger urges to consume alcohol.

Baseline, immediately after completion of the 2-week intervention
Change of the compulsive drinking behavior
Délai: Baseline, immediately after completion of the 2-week intervention

Compulsive drinking behavior will be measured by the short form of the Obsessive-Compulsive Drinking Scale (OCDS). The total score of OCDS ranges from 0 to 40, with higher scores reflecting greater obsessive-compulsive thoughts and behaviors related to alcohol use.

Baseline, immediately after completion of the 2-week intervention
Side effects of the modulation
Délai: Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period

Side effects will be assessed using a standardized adverse reaction evaluation form. The presence and severity of stimulation-related adverse reactions will be recorded for each symptom.

Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
Change of depressive symptoms.
Délai: Baseline, immediately after completion of the 2-week intervention

Depressive symptoms will be measured using the 17-item Hamilton Depression Rating Scale (HAMD-17). The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms.

Baseline, immediately after completion of the 2-week intervention
Change of anxiety symptoms
Délai: Baseline, immediately after completion of the 2-week intervention

Anxiety symptoms will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). The total score ranges from 0 to 56, where higher scores reflect greater anxiety severity.

Baseline, immediately after completion of the 2-week intervention
Change of the self-control ability
Délai: Baseline, immediately after completion of the 2-week intervention

Self-control ability will be measured using the Self-Control Scale (SCS). The total score ranges from 19 to 95, with higher scores of SCS indicating better self-regulation and impulse control.

Baseline, immediately after completion of the 2-week intervention
Change of the risky decision-making performance
Délai: Baseline, immediately after completion of the 2-week intervention

Risky decision-making will be assessed using the Balloon Analogue Risk Task (BART), with task performance and concurrent electroencephalography (EEG) measures related to risk-taking, decision-making, and outcome processing recorded. In addition, the Pig Dice Game will be administered during functional magnetic resonance imaging (fMRI) to assess risk-taking decision-making and associated task-related brain activity. Behavioral and neuroimaging measures derived from these tasks will be used to characterize changes in risk-related decision-making.

Baseline, immediately after completion of the 2-week intervention
Change of the inhibitory control performance
Délai: Baseline, immediately after completion of the 2-week intervention

Inhibitory control will be assessed using the Stop-Signal Task (SST), with task performance evaluated together with concurrent electroencephalography (EEG) measures related to response inhibition and inhibitory control.

Baseline, immediately after completion of the 2-week intervention
Change of the resting state neural activity.
Délai: Baseline, immediately after completion of the 2-week intervention

Resting-state functional magnetic resonance imaging (rsfMRI) will be used to assess intrinsic brain activity and functional connectivity. Resting-state electroencephalography (rsEEG) will be employed to assess spontaneous neural oscillatory activity.

Baseline, immediately after completion of the 2-week intervention

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Individualized Electric Field Simulation
Délai: Baseline, immediately after completion of the 2-week intervention

Individualized head models will be constructed using structural magnetic resonance imaging (sMRI), including T1-weighted imaging and diffusion tensor imaging (DTI). The electric field induced by HI-tACS will be simulated to characterize its spatial distribution and interindividual variability in modeled stimulation exposure.

Baseline, immediately after completion of the 2-week intervention
Change of the molecular-level neurochemistry
Délai: Baseline, immediately after completion of the 2-week intervention

SPICE magnetic resonance spectroscopic imaging will be used to explore changes in brain neurochemical profiles following HI-tACS. Metabolite-related signals and their spatial distributions will be assessed to characterize potential intervention-associated neurochemical alterations. Individual metabolite measurements will be analyzed separately, with their respective quantification methods and measurement units reported.

Baseline, immediately after completion of the 2-week intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 octobre 2026

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

31 décembre 2026

Dates d'inscription aux études

Première soumission

10 novembre 2025

Première soumission répondant aux critères de contrôle qualité

10 novembre 2025

Première publication (Réel)

12 novembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner